摘要: With the acceptance of antibodies as therapeutics, a diversity engineered antibody forms have been created to improve their efficacy, including enhancing effector functions full-length antibodies, delivering toxins kill cells or cytokines in order stimulate immune system, and bispecific target multiple receptors. After years vitro investigation, many these are now moving into clinical trials showing promise. A potential new type function for that is, generation reactive oxygen species may effect inflammation bacterial killing, has elucidated. In addition, field expanded beyond concentration on immunoglobulin G include therapeutics.
elsevier.com
sci-hub.se 参考文章(63)
Felix Schlachetzki, Chunni Zhu, William M. Pardridge, Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier Journal of Neurochemistry. ,vol. 81, pp. 203- 206 ,(2002) , 10.1046/J.1471-4159.2002.00840.X
Annemiek B. van Spriel, Marjolein van Egmond, Jan G. J. van de Winkel, Evert van Garderen, Hans Vermeulen, Gerwin Huls, Enhancement of Polymorphonuclear Cell-mediated Tumor Cell Killing on Simultaneous Engagement of FcγRI (CD64) and FcαRI (CD89) Cancer Research. ,vol. 61, pp. 4055- 4060 ,(2001)
Robert L Shields, Angela K Namenuk, Kyu Hong, Y Gloria Meng, Julie Rae, John Briggs, Dong Xie, Jadine Lai, Andrew Stadlen, Betty Li, Judith A Fox, Leonard G Presta, None, High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR Journal of Biological Chemistry. ,vol. 276, pp. 6591- 6604 ,(2001) , 10.1074/JBC.M009483200
V. Budagian, P. Nanni, P. L. Lollini, P. Musiani, E. DI Carlo, E. Bulanova, R. Paus, S. Bulfone-Paus, Enhanced inhibition of tumour growth and metastasis, and induction of antitumour immunity by IL-2-IgG2b fusion protein. Scandinavian Journal of Immunology. ,vol. 55, pp. 484- 492 ,(2002) , 10.1046/J.1365-3083.2002.01081.X
N D James, P J Atherton, J Jones, A J Howie, S Tchekmedyian, R T Curnow, A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer British Journal of Cancer. ,vol. 85, pp. 152- 156 ,(2001) , 10.1054/BJOC.2001.1878
Sergey M. Kipriyanov, Björn Cochlovius, Holger J. Schäfer, Gerhard Moldenhauer, Alexandra Bähre, Fabrice Le Gall, Stefan Knackmuss, Melvyn Little, Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. Journal of Immunology. ,vol. 169, pp. 137- 144 ,(2002) , 10.4049/JIMMUNOL.169.1.137
Miriam Hursey, Dianne L. Newton, Hans J. Hansen, Dale Ruby, David M. Goldenberg, Susanna M. Rybak, Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics. Leukemia & Lymphoma. ,vol. 43, pp. 953- 959 ,(2002) , 10.1080/10428190290021380
Manuel L. Penichet, Jay S. Dela Cruz, Seung-Uon Shin, Sherie L. Morrison, A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Human antibodies. ,vol. 10, pp. 43- 49 ,(2001) , 10.3233/HAB-2000-10107
Theresa M Allen, Puja Sapra, Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Research. ,vol. 62, pp. 7190- 7194 ,(2002)
Jennifer H. Anolik, Debbie Campbell, Raymond E. Felgar, Faith Young, Inaki Sanz, Joseph Rosenblatt, R. John Looney, The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus Arthritis & Rheumatism. ,vol. 48, pp. 455- 459 ,(2003) , 10.1002/ART.10764